CStone Pharmaceuticals (2616) Stock Statistics & Valuation Metrics

CStone Pharmaceuticals has a market cap or net worth of HK$7.37B. The enterprise value is HK$10.71B.

CStone Pharmaceuticals has 1,600,249,100 shares outstanding. The number of shares has decreased by -2.65% in one year.

CStone Pharmaceuticals’s return on equity (ROE) is -0.71 and return on invested capital (ROIC) is -41.59%.

The current PE Ratio of CStone Pharmaceuticals is ―. CStone Pharmaceuticals’s PEG ratio is -0.05.

In the last 12 months, CStone Pharmaceuticals had revenue of 269.58M and earned -437.00M in profits. Earnings per share was -0.31.

In the last 12 months, operating cash flow was -352.84M and capital expenditures 0.00, giving a free cash flow of -352.84M billion.

CStone Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CStone Pharmaceuticals upcoming earnings date is Aug 20, 2026, TBA (Confirmed).

CStone Pharmaceuticals as a current ratio of 2.18, with Debt / Equity ratio of 56.51%

In the past 12 months, CStone Pharmaceuticals has paid 13.06M in taxes.

CStone Pharmaceuticals EV to EBITDA ratio is -15.27, with an EV/FCF ratio of -18.82.

CStone Pharmaceuticals has HK$919.09M in cash and marketable securities with HK$348.67M in debt, giving a net cash position of HK$570.43M billion.

Gross margin is 39.88%, with operating margin of -160.48%, and net profit margin of -162.10%.

The average price target for CStone Pharmaceuticals is HK$9.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy